The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

Moderna stock took a beating in January after the company slashed its outlook for 2024 and 2025 and missed the mark in a CMV ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

Moderna advances combo vaccine for flu and COVID-19 with trials starting in March Pharmaceutical companies gear up to tackle ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus.

The intervening years have both sped and crawled by, too busy at times to take stock of all that has changed, too plodding to ...

Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne disease. The French biotech ...

Today, there’s also a more traditional vaccine made by Novavax, and some countries have tried additional options. Rollout to ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in the U.S., the agency has cleared an under-the-skin version of the ...